Pharmaceuticals, Biotechnology & Life Sciences

Read how Eli Lilly’s 2026 earnings forecast, Zepbound/Foundayo gains, and a $2.25 B gene‑editing partnership could boost investor confidence amid GLP‑1 competition.

Zoetis Q1 2026 highlights a 2.3 % revenue rise, AI‑driven biologic growth, and a ₹1.25/share dividend, underscoring strong cash flow and strategic partnerships.

Merck KGaA’s steady focus on biosafety testing keeps its shares steady amid market volatility, offering investors a reliable, cross‑sector growth outlook.

Pfizer’s interim MagnetisMM‑5 data show ELREXFIO improves progression‑free survival in RRMM, promising a premium price and strong market impact.

Agilent Technologies’ latest report shows how high‑margin RF modules fuel growth and offer a blueprint for pharma and biotech firms tackling market access, patent cliffs, and M&A in fast‑moving sectors.

Fosun Pharma partners with Arcera Life Sciences to accelerate neurodegenerative, oncology, and rare disease therapies—boosting global access to next‑gen drugs, including Alzheimer’s breakthroughs.

WuXi AppTec Q1 2024 earnings: 40% revenue growth, 70% profit jump, & a strong GLP‑1 pipeline, boosting margins and investor confidence.

Astellas Pharma’s settlement with MSN allows a generic Myrbetriq launch while securing steady royalties, boosting cash flow and supporting its regenerative‑medicine focus.

AbbVie’s Q1 2026 earnings show $4.72 bn in revenue, a 3.8 % rise driven by Humira and oncology products, while $7.9 bn R&D fuels a robust pipeline of next‑generation biologics.

Healthcare delivery amid shifting economics: How value‑based contracts, AI, tele‑health and workforce strategies can boost margins, quality, and patient access.